Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology (NYSE:MAIA) announced on March 2, 2026 that it has commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants, with a 30-day underwriter option for additional shares.
Use of proceeds is intended for clinical trials, working capital, and general corporate purposes. The offering is made from an existing Form S-3 shelf registration and is subject to market conditions and SEC filing of a prospectus supplement.
MAIA Biotechnology (NYSE American: MAIA) on Feb 24, 2026 highlighted Phase 3 progress for lead candidate ateganosine, described as the first direct telomere‑targeting anticancer agent in development. The company cited an FDA Fast Track designation, a targeted 3L NSCLC population of ~50,000 US patients, and a potential $50 billion global immunotherapy market opportunity.
Management reported that ateganosine sequenced with immune checkpoint inhibitors has shown outcomes that exceed historical CPI or chemotherapy results and framed the program as a potential new treatment category for advanced NSCLC.
MAIA Biotechnology (NYSE: MAIA) provided a corporate update on Jan 20, 2026 outlining 2025 achievements and targeted 2026 clinical milestones for ateganosine, a telomere-targeting immunotherapy. Key 2025 items include FDA Fast Track designation, initiation of a pivotal THIO-104 Phase 3 in 3L NSCLC, Part C expansion of the THIO-101 Phase 2 into Asia and Europe, a $2.3M NIH grant, strategic combination agreements with Roche and BeOne, and ~$17.6M capital raised in 2025. MAIA cites strong 2025 efficacy data and a projected 18–24 month path toward potential early commercial approval, with planned interim Phase 3 efficacy readouts and continued FDA engagement in 2026.
MAIA (NYSE American: MAIA) announced that independent directors participated in a private placement that closed on December 22, 2025, with three directors buying a total of 179,737 shares and 179,737 warrants at an average price of $1.224.
Gross proceeds from the offering were approximately $1.51 million. Directors and officers now hold 5,019,857 shares, equal to 13.43% of MAIA. The company said the financing reflects confidence in ateganosine, its first-in-class anticancer therapy; MAIA launched a pivotal Phase 3 international trial in December 2025 and the FDA granted Fast Track designation for ateganosine in NSCLC.
MAIA Biotechnology (NYSE American: MAIA) entered definitive agreements for a private placement of 1,233,488 shares of common stock at $1.224 per share and accompanying warrants to buy one share at an exercise price of $1.36.
The warrants become exercisable six months after issuance, expire three years from issuance, and the offering is expected to close on or about December 18, 2025. Gross proceeds are expected to be approximately $1.51 million prior to offering expenses. The company intends to use net proceeds to fund Step 1 of Part C of the Phase II THIO-101 trial and for working capital.
MAIA (NYSE American: MAIA) announced initiation of a pivotal Phase 3 trial for ateganosine on Dec 11, 2025, following ongoing Phase 2 data described as surpassing expectations in advanced non‑small cell lung cancer (NSCLC). The U.S. FDA has granted Fast Track designation for ateganosine in NSCLC. The company describes ateganosine as a first‑in‑class, direct telomere‑targeting agent with a dual mechanism that combines telomere disruption and immune activation via cGAS/STING and T‑cell responses.
Management cited statistical assessments indicating a very high probability of technical success for regulatory approval; Phase 3 outcomes are now the next milestone for potential commercialization.
MAIA (NYSE:MAIA) announced the first patient dosing in the THIO-104 Phase 3 pivotal trial of ateganosine given in sequence with a checkpoint inhibitor (CPI) as a third-line treatment for advanced non-small cell lung cancer (NSCLC).
The multicenter, open-label trial will randomize up to 300 patients 1:1 to ateganosine+CPI versus investigator’s choice chemotherapy, with overall survival as the primary endpoint. MAIA has regulatory approval to screen in Taiwan, Turkey, select EMA countries, and Georgia; screening and enrollment are underway.
Supporting data cited: prior THIO-101 observed PFS 5.6 months versus ~2.5 months standard of care, one patient reached 30 months survival, and the FDA has granted Fast Track designation for ateganosine in NSCLC.
MAIA (NYSE American: MAIA) reported additional insider open-market purchases and highlighted clinical progress for its small-molecule telomere-targeting therapy ateganosine.
Directors and officers acquired approximately 182,445 shares between Nov 21–28, 2025, and continue to hold 4,480,120 shares (12.95%) of the company. The company said ateganosine is advancing through mid‑ to late‑stage development with encouraging clinical signals in advanced non‑small cell lung cancer (NSCLC).
MAIA (NYSE:MAIA) announced progress for its telomere-targeting candidate ateganosine as a potential new class for advanced non-small cell lung cancer (NSCLC) on Dec 10, 2025. MAIA said ateganosine has received FDA Fast Track designation for NSCLC patients resistant to immunotherapy and chemotherapy and that it is initiating a Phase 3 THIO-104 trial.
The release highlights market context and figures: the CPI category generated about $50B in 2024, NSCLC market value cited at $34.1B now and projected to $68.8B by 2033, ~180,000 U.S. NSCLC patients entering treatment annually, and Keytruda revenue of $29.5B in 2024. Ateganosine also holds FDA orphan drug designations for glioblastoma, HCC, and SCLC, each conferring seven years of U.S. exclusivity if approved.
MAIA Biotechnology (NYSE American: MAIA) announced that the CEO and certain directors purchased approximately 182,445 shares of MAIA common stock in open-market trades between November 21 and 28, 2025 at an average price of $1.06 per share. Vlad Vitoc, chairman and CEO, purchased 94,300 shares at an average of $1.08, while directors Cristian Luput and Stan V. Smith purchased a combined 88,145 shares at an average of $1.04.
The company highlighted clinical progress for ateganosine in its Phase 2 THIO-101 trial, reporting a 38% response rate and 17.8 months overall survival to date.